AbbVie (ABBV)
(Delayed Data from NYSE)
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $197.50 -0.05 (-0.03%) 9:08 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.55 USD
+1.18 (0.60%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $197.50 -0.05 (-0.03%) 9:08 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Novartis' Cosentyx Superior to Stelara in Psoriasis Study
by Zacks Equity Research
Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,
Bristol-Myers Gets FDA Nod for Orencia's Label Expansion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).
Galapagos-Gilead Begin Phase II Study on Uveitis Candidate
by Zacks Equity Research
Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.
Bayer Starts Phase III Study for Uterine Fibroids' Candidate
by Zacks Equity Research
Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.
Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU
by Zacks Equity Research
Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.
Gilead's (GILD) HCV Drug Application Accepted in the EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.
AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
by Zacks Equity Research
Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.
Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx
by Zacks Equity Research
Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
by Arpita Dutt
Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.
AbbVie (ABBV) Announced Positive Phase III RA Candidate Data
by Zacks Equity Research
AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).
Novartis Biosimilar Pipeline, 2018 Growth Plans on Track
by Zacks Equity Research
Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.
Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug
by Arpita Dutt
Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
by Zacks Equity Research
AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),
New Stock Research Reports for Boeing, AbbVie and UnitedHealth
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV) and UnitedHealth (UNH).
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
by Zacks Equity Research
Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.
AbbVie and J&J Present Positive Imbruvica Leukemia Data
by Zacks Equity Research
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
by Arpita Dutt
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.